Gland Pharma Ltd. · NSE:GLAND
Gland Pharma — Q2 FY2023 Earnings Presentation
12 slides from Gland Pharma's earnings presentation, Oct 26, 2022
Slide 1: Gland Pharma Limited – Investor Presentation on Q2FY23 Financial Results
GLAND GLAND PHARMA LIMITED October 26, 2022 BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, 5th floor 25th floor, Dalal Street Plot no. C-1, Block G, Bandra Kurla Complex Mumbai - 400 001 Bandra (East
Slide 2: Gland Pharma Limited Financial Results Q2'FY23
Gland Pharma Limited Financial Results Q2’FY23 26th October 2022
Slide 3: Safe Harbor Statement
Safe Harbor Statement The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation
Slide 4: Financial Highlights (1/3)
Financial Highlights (1/3) Revenue seen recovering after being impacted by supply chain disruption Revenue from Operations EBITDA (1) / EBITDA Margin (2) (INR Mn) (INR Mn / %) - 3% 9,259 22,344 10,805 10,444 4,278 7,068 19,013 8,569 3,443 3,625 35% 37% 33% 39% 38% Q2 FY22 Q1 FY23 Q2 FY23 6M FY22 6M
Slide 5: Financial Highlights (2/3)
Financial Highlights (2/3) Strong Balance Sheet to support future growth plans Net Worth (1) Cash and Bank Balances / Net Cash (2) (INR Mn) (INR Mn) 71,576 76,511 12,250 38,200 38,162 12,250 34,483 34,444 64,261 59,326 Mar'22 Sep'22 Mar'22 Sep'22 Networth Fresh issue of equity Total Cash Net Cash Ne
Slide 6: Financial Highlights (3/3)
Financial Highlights (3/3) Focus on capital efficiency and ramping-up new capacities Asset Turnover Ratio (1)(2) ROCE (ex-cash)(3) / ROCE (4) / RONW (5) (%) 3.4 35% 33% 2.8 2.4 21% 21% 18% 13% 21% 19% 0.7 0.7 0.5 13% Total asset turnover Fixed asset turnover 6M FY22 FY22 6M FY23 6M FY22 FY22 6M FY23
Slide 7: P&L Highlights
P&L Highlights (INR Mn) YoY YoY Particulars Q2 FY23 Q2 FY22 6M FY23 6M FY22 Q1 FY23 change change Revenue from operations 10,444 10,805 -3% 19,013 22,344 -15% 8,569 Other Income (excluding Forex gain) 475 354 34% 877 696 26% 402 Forex gain (net) 181 158 15% 523 434 20% 342 Total Income 11,100 11,317
Slide 8: USA, Europe, Canada and Australia (Core Markets)
USA, Europe, Canada and Australia (Core Markets) Revenue: 6M FY23: Rs. 14,531 Mn Q2 FY23: Rs. 7,475 Mn YoY Change: -1% YoY Change: 3% We delivered a growth of 3% y-o-y in our core markets and a growth of 5% y-o-y in the USA market. Our key launch in the US market during the quarter was Core Market
Slide 9: Rest of the World Markets
Rest of the World Markets The material supply issues are starting to improve and 6M FY23: Rs. 3,246 Mn Q2 FY23: Rs. 2,243 Mn we are ensuring we build sufficient inventory along with YoY Change: -29% YoY Change: -3% qualifying alternate suppliers. Rest of the World Markets We saw a de-growth of 3
Slide 10: India (Domestic Market)
India (Domestic Market) 6M FY23: Rs. 1,236 Mn Q2 FY23: Rs. 726 Mn India market sales accounted for 7% of our total sales YoY Change: -60% YoY Change: -42% during Q2 FY23. We completed the Insulin line modifications and it was India (Domestic Market) available for commercial production during thi
Slide 11: Growth Drivers
Growth Drivers 1 China remains a key geographic focus and we expect to start receiving approvals for products during the Geographic current year as the inspection has been waived off Expansion We are expanding our penetration in the rest of the world markets such as South Africa and Kazakhstan 2
Slide 12: Registered and Corporate Office
Registered Office Corporate Office: Gland Pharma Limited Gland Pharma Limited Survey No. 143-148, 150 & 151 Plot No. 11 & 84, TSIIC Phase: IV Near Gandimaisamma 'X' Roads Pashamylaram (V), Patancheru (M), D.P. Pally, Dundigal Gandimaisamma Mandal Sangareddy District Medchal-Malkajgiri District Hyder